GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

 GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) — Greater Cannabis Company, Inc. (GCANRx or the Company) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid t…